Highlights

  • KORU Medical reported third-quarter net Revenue of USD 11.6 mn, an 11% year-over-year increase.
  • Gross Margin improved to 65.2% from 60.2% in the corresponding prior-year reporting period.
  • The company recorded its second consecutive quarter of positive Net Income and adjusted EBITDA.
  • KORU revised full-year 2026 revenue guidance to USD 48.0 mn–48.5 mn and added distribution agreements.

KORU Medical Systems (NASDAQ:KRMD) is drawing fresh attention after its latest developments put koru medical q3 2026 profitability and revenue at the centre of its Investment narrative. The company’s disclosed milestones offer a clearer look at operating priorities, financial resources and what remains to be completed. Against that backdrop, shares gained 23.10% to USD 3.89 in the November 11, 2026 market figures. The distinction between progress already reported and milestones still planned remains essential when evaluating its next phase.

Profitable Growth Extends into the Third Quarter

KORU Medical reported third-quarter 2026 revenue of USD 11.6 mn, 11.2% above the corresponding year-earlier quarter. Gross Profit climbed 20% to USD 7.5 mn as gross margin increased to 65.2% from 60.2%.

The medical technology company develops and supplies large-volume subcutaneous infusion solutions. It recorded net income of USD 0.2 mn compared with a net loss of USD 0.8 mn in the prior-year period, marking a second consecutive profitable quarter.

Domestic Sales and Distribution Developments

Domestic core revenue rose 31.6% to USD 8.1 mn, reflecting higher pump and consumable volumes, new patient starts and changing distributor purchasing patterns. International core revenue reached USD 3.1 mn, down 16.5% on a reported basis.

KORU also signed two sales and distribution agreements with partners in Europe and Africa. Those arrangements extend its international distribution footprint, although the company did not present them as realised revenue contributions.

Operating Metrics Show Progress

Adjusted EBITDA was USD 1.3 mn compared with USD 0.1 mn in the third quarter of 2025. The measure is non-GAAP and should be considered alongside reported net income.

For the first nine months of 2026, the company generated USD 35.4 mn of net revenue, increasing 17%. Cash and cash equivalents totalled USD 7.4 mn at September 30.

Updated Full-Year Targets

KORU increased the lower end of its revenue guidance, now expecting USD 48.0 mn–48.5 mn in full-year 2026 sales. It also forecast gross margin of 63%–64%, reiterated positive full-year adjusted EBITDA and raised its year-end cash expectation to more than USD 8 mn.

These targets set out management’s expectations for the remainder of 2026 and are not completed financial outcomes.

What Comes Next

For KORU Medical Systems, the near-term focus remains the milestones outlined in its latest announcements rather than an assumed outcome. The developments described above combine confirmed activity with expectations that remain subject to company execution, regulatory processes where applicable, and later reporting. Those distinctions will matter as subsequent updates provide more information about timing and progress.

KORU Medical Systems shares traded at USD 3.89, up 23.10%, in the November 11, 2026 market figures.